Monomethyl fumarate

Generic Name: Monomethyl fumarate

Brand Names: Bafiertam

Drug Type: Small Molecule

Chemical Formula: C_₅H_₆O_₄

CAS Number: 2756-87-8

Unique Ingredient Identifier: 45IUB1PX8R

Clinical Trials

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Phase 4

Conditions: Hematopoietic Stem Cell Transplantation

Interventions: Drug: ATG
Drug: CsA
Drug: MTX
Drug: MMF

First Posted Date: 2019-12-18

Last Posted Date: 2019-12-18

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 266

Registration Number: NCT04203108

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Bafiertam
Drug: Tecfidera

First Posted Date: 2019-07-17

Last Posted Date: 2020-01-18

Lead Sponsor: Banner Life Sciences LLC

Target Recruit Count: 210

Registration Number: NCT04022473

Locations: 🇺🇸
BioPharma Services, Inc., Columbia, Missouri, United States

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Phase 2

Recruiting

Conditions: Systemic Sclerosis

Interventions: Other: Placebo Subcutaneous Injection
Drug: Belimumab
Other: Placebo Infusion
Drug: Rituximab
Drug: MMF

First Posted Date: 2019-02-18

Last Posted Date: 2025-03-13

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 30

Registration Number: NCT03844061

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: MMF

First Posted Date: 2018-09-06

Last Posted Date: 2018-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT03660436

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation

Phase 2

Conditions: Liver Transplantation

Interventions: Drug: Tacrolimus (Tacrolimus elimination)
Drug: Tacrolimus
Drug: MMF and/or steroids
Drug: Sirolimus

First Posted Date: 2018-04-18

Last Posted Date: 2018-04-18

Lead Sponsor: Southern Medical University, China

Target Recruit Count: 130

Registration Number: NCT03500848

Locations: 🇨🇳
First Affiliated Hospital, Sun Yat-Sen University, Guanzhou, Guangdong, China
🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

REduCing Immunogenicity to PegloticasE (RECIPE) Study

Phase 2

Completed

Conditions: Gout Chronic

Interventions: Drug: Placebo
Drug: Pegloticase 8 MG/ML [Krystexxa]
Drug: MMF

First Posted Date: 2017-10-06

Last Posted Date: 2022-03-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 35

Registration Number: NCT03303989

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Phase 3

Completed

Conditions: Takayasu Arteritis

Interventions: Drug: MMF
Drug: CYC
Drug: Glucocorticoids
Drug: MTX
Drug: AZA

First Posted Date: 2017-03-30

Last Posted Date: 2023-08-30

Lead Sponsor: Chinese SLE Treatment And Research Group

Target Recruit Count: 138

Registration Number: NCT03096275

Locations: 🇨🇳
General Hospital of Tianjing Medical University, Tianjin, China
🇨🇳
Hebei Provincial Hospital, Shijiazhuang, Hebei, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 4 locations

Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation

Conditions: Natural Killer Cell Mediated Immunity

Interventions: Drug: MMF

First Posted Date: 2016-11-30

Last Posted Date: 2020-10-05

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 200

Registration Number: NCT02978274

Locations: 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndrome
Multiple Myeloma
Lymphoplasmacytic Lymphoma
Marginal Zone B-cell Lymphoma
Prolymphocytic Leukemia
MRD Positive Leukemia
Relapsed T-Cell Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia/Lymphoma
Burkitt's Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: MMF
Drug: Sirolimus
Radiation: TBI
Biological: Umbilical cord blood cell infusion
Biological: ATG

First Posted Date: 2016-03-30

Last Posted Date: 2023-02-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT02722668

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Allo HSCT Using RIC for Hematological Diseases

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Lymphoplasmacytic Lymphoma
Mantle-Cell Lymphoma
Lymphoblastic Lymphoma
Acute Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Burkitt's Lymphoma
Hematological Diseases
B-Cell Lymphoma

Interventions: Drug: Allopurinol
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: ATG
Radiation: TBI
Drug: Tacrolimus
Drug: MMF
Biological: Peripheral Blood Stem Cells
Biological: Related or Unrelated Bone Marrow Cells

First Posted Date: 2016-01-21

Last Posted Date: 2023-09-21

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 156

Registration Number: NCT02661035

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy